Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center

CONCLUSIONS: At our institution, ICI was most commonly prescribed in the relapsed/refractory setting to patients with metastatic disease. The treatment was generally well-tolerated in the pediatric population. The overall response rate was low, and the majority of patients eventually experienced disease progression. A few patients, however, had durable treatment responses. Further studies are needed to identify which pediatric patients are most likely to benefit from ICI.PMID:38629258 | DOI:10.1002/cam4.7154

Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Ajami Gikandi Susan N Chi Kee Kiat Yeo Allison F O'Neill David S Shulman Steven G DuBois Natalie B Collins Source Type: research